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Introduction
Malawi has the highest prevalence of  cervical cancer in the 
world with an age standardized rate of  75.9 per 100,000.1 
This accounts for 45% of  all female cancers in Malawi and 
results in at least 1,600 deaths per year.2,3 Women with HIV 
have 6 to 8 times increased risk of  cervical cancer.4,5,6 Cervical 
cancer is preventable with both Human Papilloma Virus 
(HPV) vaccination and regular screening and treatment of  
pre-cancerous lesions. HPV vaccination programmes have 
been implemented in several African countries and a pilot 
project has recently been concluded in Malawi with plans 
for national scale up by 2019.7 However, even when the 
vaccine is made available, millions of  women will be beyond 
the priority age of  vaccination and screening this population 
for cervical cancer will remain crucial.8 Several studies have 
shown that screening programmes using visual inspection of  
the cervix with acetic acid (VIA) are feasible and acceptable 
in resource limited settings.9,10,11,12 A study of  VIA screening 
over 3 years in a general population of  women in India 
demonstrated a 24% reduction in incidence of  cervical 
cancer and a 35% reduction in cervical cancer mortality.13 
VIA screening has been successfully integrated into HIV 
services in several countries. In Zambia, HIV infrastructure 
was used to offer cervical cancer screening on a national 
scale.14 In Cote d’Ivoire, cervical cancer screening was 
offered to all women attending HIV services at four clinics, 
by means of  a mobile team of  midwives.15 All women 
attending an urban HIV clinic in Botswana were offered VIA 
as part of  the clinic’s services12 and in a large HIV clinic in 
Lilongwe, Malawi, hypertension and cervical cancer are also 
screened for and managed as part of  routine anti-retroviral 
(ART) services.16 
For women who screen positive for lesions suggestive of  
cervical cancer, several treatment options are available. 
Cryotherapy has been widely used in many African countries 
and is the main method used in Malawi.17 More recently 
cold coagulation has been introduced, which offers several 
potential advantages over cryotherapy.18 For locally invasive 
lesions confined to the cervix but considered too large for 
cryotherapy or cold coagulation, other options include loop 
electrical excision procedure (LEEP), cold-knife conization 
and hysterectomy.18 Cervical cancer screening programmes 
also detect patients with already advanced carcinoma, 
but treatment options for malignancies in many African 
countries remain limited due to lack of  gynaecological 
oncology expertise and radiotherapy services.19
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from wanting to discuss the procedure with their partners, 
possibly related to a recommended period of  4 weeks of  
sexual abstinence post treatment. This has been found in 
other VIA services in Malawi23. The acceptance of  same-day 
treatment in Zomba has improved as counselling experience 
in the clinic has improved over time. Thus, a combination of  
reliable equipment and good counselling, together with the 
safety net of  the electronic monitoring tool to catch those 
who chose to defer treatment, are important elements of  
future programme success. 
Conclusions
Malawi has a large unmet need for cervical cancer screening 
for all women of  reproductive age. Women who are HIV-
positive are at significantly higher risk, and those women 
who regularly attend an HIV clinic are far more accessible 
to health care workers than women in the community. 
Incorporating cervical cancer screening into services at 
HIV clinics is, therefore, a logical strategy to reduce cervical 
cancer morbidity and mortality with a high benefit to 
screening ratio.  Cervical cancer screening within an HIV 
clinic is feasible, although it required additional inputs of  
staff  to run a daily service in Zomba. A structured approach 
to cervical cancer screening in the HIV clinic was important. 
This was facilitated by the modification of  the EMR, which 
aimed to match referral numbers to screening capacity and 
address the previously observed attrition in the screening to 
treatment completion cascade. Over time, this system should 
result in close to universal screening of  women attending 
the clinic.  The use of  cold coagulation as an alternative to 
cryotherapy has the potential to reduce logistical barriers to 
interruptions in equipment and supplies.  
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deferred cold coagulation to a later date (of  whom 4 came 
for treatment), and 8 (35%) were referred to surgery due to 
size of  lesion; 5/686 (0.7%) women had lesions suspicious 
of  cancer. Of  the 23 VIA positive women, 19 (82.6%) were 
within age group 31-45, 3 (13%) >45 years and only 1 (4.4%) 
<30 years. VIA positive women (N=23) were slightly older 
than VIA negative women (N=615; mean age 37.7 vs. 36.9).
Comparing data from five months prior to the implementation 
of  the modification of  the EMR to six months after the 
intervention, the monthly average of  women receiving VIA 
screening from the HIV clinic for the first time showed little 
change (from 64 to 61 women per month). However, the 
percentage of  women who received cryotherapy the same 
day increased from 33% (n=3) to 83% (n=5). 
Discussion
Before the implementation of  the EMR modification, many 
women who were referred from the HIV clinic for cervical 
cancer screening did not undergo screening.  As no women 
were turned away from VIA services, they likely chose not to 
attend VIA screening due to long waiting lines. The cervical 
cancer EMR is designed to match the numbers referred 
daily to screening capacity.The rate of  testing positive for 
VIA, 3.4 %, is lower than reported in other services for HIV 
positive women in Malawi (10.4%)23, Zambia (31.8%)26 and 
Botswana (11.6%)12. There are several possible explanations 
for this. The nurse provider has many years’ experience in 
cervical cancer screening and several studies have shown 
that rates of  VIA positive lesions decrease over time as 
providers gain experience23, 26. Zomba Hospital HIV clinic 
has many patients who are stable on long term ART and 
many asymptomatic patients that have recently started ART. 
As such, the immune status of  many in the clinic may more 
closely resemble those of  HIV negative patients. 
In order for VIA programmes to be effective, it is essential 
that treatment be available for pre-cancerous lesions. In 
particular, it is important that cryotherapy is available on 
the same day of  diagnosis as it has been well documented 
that women often do not return for follow up. For example, 
in  Zambia, 22% of  women that chose to defer cryotherapy 
did not return for treatment27. In this regard, cryotherapy 
is widely known to present operational challenges because 
it requires large tanks of  carbon-dioxide or nitrous-oxide 
and the freezing units can malfunction28. An audit in Malawi 
of  VIA services at 21 facilities found that cryotherapy was 
working at only 7 facilities and working N2O tanks at only 
5 facilities20. Cold coagulation is an alternative form of  
treatment to cryotherapy. In a randomized control trial, cold 
coagulation produced similar cure rates of  95.5% compared 
to 93.8% of  cryotherapy29. In a meta-analysis of  4,569 
cervical intraepithelial neoplasia (CIN) patients treated with 
cold coagulation, cure rates for CIN 1 were 96% and for 
CIN 2 – 3 were 95%30. As cold coagulation uses electric 
current rather than gas, ongoing supplies are not needed 
and availability of  same-day treatment may therefore be 
better ensured in resource limited settings such as Malawi. 
Experience at one site in Malawi with the cold coagulator 
showed high acceptability with users and patients and a cure 
rate of  85% among 51 patients who came for follow up at 
one year23.
At Zomba, there has been uninterrupted availability and 
functioning of  the cold coagulator since it was purchased 
in December 2015 to present. However, several women 
still chose not to have same-day treatment, apparently 
The Malawi Ministry of  Health has adopted VIA as the 
method of  screening for cervical cancer.17 When pre-
cancerous lesions are detected, they are treated with 
cryotherapy. VIA is available at most district hospitals, but 
cryotherapy is often unavailable due to broken machines or 
lack of  gas.20 Although national HIV guidelines recommend 
that all HIV positive women receive VIA annually21, this has 
not been widely implemented. Cervical cancer screening had 
been available for many years at Zomba Central Hospital, 
but the service had often been poorly staffed and under-
equipped, with no structured system for referring HIV 
positive women for cervical cancer screening.
In October 2015, Dignitas International, a medical and 
research organization, together with the Malawi Ministry 
of  Health, established cervical cancer screening at the HIV 
clinic at Zomba Central Hospital. This was part of  a broader 
initiative to fully integrate HIV and non-communicable 
disease (NCD) care where all adults accessing care in the HIV 
clinic are screened and treated for hypertension, diabetes and 
cervical cancer.22 We describe the process and outcomes of  
the integration of  HIV care with cervical cancer screening, 
including innovations used and challenges encountered. 
Methods
Setting
Zomba District is one of  the most densely populated districts 
in Malawi with 670,500 inhabitants at the time of  this study. 
The HIV clinic at Zomba Central Hospital in Malawi has 
over 6, 500 patients in care, of  whom around 3,700 are adult 
women 20 years and older. It has been supported by Dignitas 
International since 2004 in the provision of  supplementary 
clinical, laboratory and counseling staff  and technical 
assistance. 
Implementation of integrated cervical cancer 
screening at the HIV clinic
As part of  the NCD integration initiative, new equipment 
was purchased and new staff  was trained. The broken 
existing cryotherapy machine was replaced with a cold 
coagulator. Experience elsewhere in Malawi had shown 
the difficulties in maintaining cryotherapy equipment20 and 
the relative robustness of  cold coagulation equipment.23 
Cryotherapy uses carbon dioxide gas to freeze a metal probe 
which is then applied to the cervix. A systematic literature 
review of  32 articles has found cure rates of  98.5% for all 
grades of  pre-cancerous lesions at 12 months follow up using 
cryotherapy.24 Cold coagulation involves using a metallic 
probe heated to 100-120 °C (relatively low temperatures 
compared to other devises causing coagulation) and leads 
to thermal destruction of  cervical tissue. Advantages of  
cold coagulation equipment include its small size and thus 
portability, minimal use of  electricity and shorter time of  
treatment compared to cryotherapy. 
Screening was conducted in a room adjacent to the HIV 
clinic. Screening was offered to all eligible women in HIV 
care by expert clients (ECs) who are patients on ART, are 
open about their HIV status and have shown exemplary 
adherence.  The VIA service operates daily and is coordinated 
by an experienced nurse employed by Dignitas International 
with support from Ministry of  Health nurses. HIV-
uninfected women were also screened in the VIA clinic and 
approximately 50% of  the VIA clients were HIV-uninfected. 
Due to the design of  data collection, it was not possible 
to collect data on the outcomes of  these HIV-uninfected 
women.
Although the national guidelines promoted annual VIA 
screening of  HIV positive women21, a decision was made 
to initially reduce the frequency to every three years. This 
was believed to be more achievable with available capacity, 
and was in line with World Health Organisation guidelines.25 
At every clinic visit, all women over the age of  20 were 
asked for the date of  their last VIA screening test. If  they 
had never been screened, or the date was over three years 
ago, then VIA was offered. If  the woman accepted, she 
was accompanied to the VIA room by an expert client. Pre-
cancerous lesions found using VIA were treated with cold 
coagulation or if  considered too large, the women were 
referred to a gynaecologist.
Data collection
Data were collected using the existing VIA register that was 
modified to enable capturing of  those who attended the 
HIV clinic.
After six months of  implementation, several challenges 
became apparent: many women referred for VIA did not 
attend the screening clinic or undergo screening. In addition, 
some women with pre-cancerous lesions elected to defer 
treatment with cold coagulation but did not return for care. 
As a response to the above two challenges, a modification 
to the existing HIV programme, Electronic Medical 
Record (EMR), was developed to incorporate VIA. This 
modification reminds clinicians about when VIA is due, 
limits daily numbers of  referrals to match capacity, asks 
clinicians to check if  women went to VIA when referred 
and alerts clinicians to women who had a positive VIA 
but did not receive same-day treatment (see figure 1). This 
modification was implemented in October 2016. 
Ethics approval was not sought for this study as it utilises 
data that is routinely collected and anonymised. The data is 
used in routine reporting for monitoring of  service delivery 
of  a medical program. All data can be requested from the 
Ministry of  Health through the corresponding author.
Results
We evaluated cervical cancer screening visits in 957 women 
who were referred from the HIV clinic between May 2016 
and March 2017. Of  the 686 (71%) women who underwent 
first ever screening, 23(3.4%) were found to have VIA 
positive lesions suggestive of  pre-cancer, of  whom 8 
(35%) had a same-day cold coagulation procedure, 7 (30%) 
Figure1: Screenshot of VIA modification to Electronic Medical 
Record
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